No Data
No Data
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's Is How to Trade
Foghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy Rating
Express News | HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Foghorn Therapeutics Analyst Ratings
Wedbush Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
No Data